Marc Massiot appointed to Guerbet’s Board of Directors
31 Maggio 2021 - 6:00PM
Marc Massiot appointed to Guerbet’s Board of Directors
Marc Massiot appointed
to Guerbet’s Board of Directors
Villepinte (France), May 31, 2021 (6:00
p.m. CET) – Guerbet (FR0000032526 GBT), a global leader in
medical imaging, has announced the election of Marc Massiot as
director for a six-year term. This nomination was approved at
Guerbet’s Annual General Shareholders’ Meeting on May 28.
Marc Massiot, aged 60, is
founder and manager of Enaxante, a business advisory and training
firm operating in the field of healthcare, as well as Espace Santé
Saint-Bernard, a physiotherapy and osteopathy practice.
Marc is a graduate in massage, physiotherapy and
osteopathy, a healthcare executive, and holds a Master’s degree in
Education Science Research and in Budget and Management from the EM
Lyon Business School in France. He has previously held management
positions in medical device companies.
He has also provided training for healthcare
executives and physiotherapists and was a member of the Conseil
supérieur des professions paramédicales (High Council of
Paramedical Professions) committee of physiotherapists as Competent
Person to the Ministry of Health.
Marc Massiot is a member of the Guerbet family
and General Secretary of its Shareholders’ Agreement.
Céline Lamort’s mandate was renewed for a period
of six years at this same annual meeting.
The Guerbet Board of Directors
is composed of twelve directors:
- Marie-Claire Janailhac-Fritsch, Chairwoman -
Marion Barbier- Olivier Fougère (employee director)- Mark Fouquet-
Eric Guerbet- Didier Izabel- Céline Lamort- Nicolas Louvet- Marc
Massiot- Claire Massiot-Jouault- Jean-Sébastien Raynaud (employee
director)- Thibault Viort
About
Guerbet
At Guerbet, we build lasting relationships so
that we enable people to live better. This is our purpose. We are a
leader in medical imaging worldwide, offering a wide range of
pharmaceutical products, medical devices, digital and AI solutions
for diagnostic and interventional imaging. A pioneer since 95 years
in the field of contrast media with over 2,600 people globally, we
are continuously innovating with 10% of revenue dedicated to
Research & Development and four centers in France, Israel and
the United States. Guerbet (GBT) is listed on Euronext Paris
(segment B – mid caps) and generated €712 million in revenue in
2020. For more information, please visit www.guerbet.com.
Media
relations
Guerbet GlobalAlize RPCaroline
Carmagnol / +33 (0)6 64 18 99 59 / guerbet@alizerp.com
- Guerbet Press Release-Nomination Director-May 31 2021
Grafico Azioni Guerbet (EU:GBT)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Guerbet (EU:GBT)
Storico
Da Apr 2023 a Apr 2024
